ATE150976T1 - Impfstoff-konjugate zur behandlung von vogelkrankheiten - Google Patents

Impfstoff-konjugate zur behandlung von vogelkrankheiten

Info

Publication number
ATE150976T1
ATE150976T1 AT90917281T AT90917281T ATE150976T1 AT E150976 T1 ATE150976 T1 AT E150976T1 AT 90917281 T AT90917281 T AT 90917281T AT 90917281 T AT90917281 T AT 90917281T AT E150976 T1 ATE150976 T1 AT E150976T1
Authority
AT
Austria
Prior art keywords
live virus
treatment
subject
neutralizing
vaccine conjugates
Prior art date
Application number
AT90917281T
Other languages
German (de)
English (en)
Inventor
Craig E Whitfill
Tommy L Fredericksen
Julius K Tyczkowski
James Paul Thaxton Jr
John A Dr Thoma
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Application granted granted Critical
Publication of ATE150976T1 publication Critical patent/ATE150976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT90917281T 1989-10-02 1990-10-01 Impfstoff-konjugate zur behandlung von vogelkrankheiten ATE150976T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41603589A 1989-10-02 1989-10-02
US48067890A 1990-02-15 1990-02-15
US58685990A 1990-09-24 1990-09-24

Publications (1)

Publication Number Publication Date
ATE150976T1 true ATE150976T1 (de) 1997-04-15

Family

ID=27411077

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90917281T ATE150976T1 (de) 1989-10-02 1990-10-01 Impfstoff-konjugate zur behandlung von vogelkrankheiten
AT96111909T ATE200735T1 (de) 1989-10-02 1990-10-01 Impfstoffkonjugat

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96111909T ATE200735T1 (de) 1989-10-02 1990-10-01 Impfstoffkonjugat

Country Status (11)

Country Link
US (4) US5397569A (enExample)
EP (2) EP0495008B1 (enExample)
AT (2) ATE150976T1 (enExample)
AU (2) AU6714290A (enExample)
BR (1) BR9007702A (enExample)
CA (1) CA2066661C (enExample)
DE (2) DE69030383T2 (enExample)
DK (2) DK0755684T3 (enExample)
ES (2) ES2158200T3 (enExample)
IL (1) IL95867A (enExample)
WO (1) WO1991004749A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
JPH07206705A (ja) 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
US5807551A (en) * 1996-04-01 1998-09-15 Iowa State University Research Foundation, Inc. Method to provide artificial passive immunity in birds
AU715555B2 (en) 1996-09-30 2000-02-03 University Of Arkansas, The Method of producing active immunity with vaccine conjugate
JP5209160B2 (ja) * 1999-08-24 2013-06-12 エービーアイシー・バイオロジカル・ラボラトリーズ・リミテッド ワクチン組成物およびその使用方法
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
US6682754B2 (en) * 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
EP1161953A3 (en) * 2000-06-09 2004-02-04 Akzo Nobel N.V. IBDV strain for in OVO administration
ZA200104596B (en) * 2000-06-09 2001-12-06 Akzo Nobel Nv IBDV strain for in ovo administration.
US7037506B2 (en) 2002-03-08 2006-05-02 Schweltzer Chemical Corporation Ltd. Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
US7029681B2 (en) 2002-03-08 2006-04-18 Schweitzer Chemical Corporation Multiple and multivalent DNA vaccines in ovo
US7265211B2 (en) 2002-03-22 2007-09-04 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of making
US6729265B2 (en) * 2002-06-27 2004-05-04 Arkion Life Sciences Llc Supplemented antibody feed to enter the circulating system of newborns
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2008147847A1 (en) * 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
WO2014110092A1 (en) * 2013-01-08 2014-07-17 Humabs Biomed Sa Methods of generating robust passive and active immune responses
CN103341164B (zh) * 2013-07-19 2015-06-24 天津瑞普生物技术股份有限公司 一种鸡传染性法氏囊病抗原抗体复合物、制剂及制备方法
BR112022004488A2 (pt) 2019-09-11 2022-05-31 Zoetis Services Llc Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2518978A (en) * 1946-09-12 1950-08-15 American Cyanamid Co Hog cholera vaccine
DE1041214B (de) * 1957-03-11 1958-10-16 Dr Med Karl Theurer Verfahren zur Herstellung von Impfstoffen gegen Viruserkrankungen
US3846543A (en) * 1963-01-02 1974-11-05 Monsanto Co Process for the separation of virus from non-viral proteins
US3326767A (en) * 1966-03-21 1967-06-20 Abbott Lab Avian leukosis treatment with inactivated rous sarcoma virus
US3651213A (en) * 1969-05-29 1972-03-21 Monsanto Co Method for the immunization of a living animal body against viral disease
US3853467A (en) * 1973-08-15 1974-12-10 Gen Electric Method and apparatus for immunological detection of biological particles
CA1039649A (en) * 1973-08-30 1978-10-03 General Electric Company Method of forming multilayer immunologically complexed films
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
EP0073856A1 (en) * 1981-08-28 1983-03-16 Gist-Brocades N.V. Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain
US4458630A (en) * 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
US4493825A (en) * 1982-10-05 1985-01-15 Iowa State University Research Foundation Purified and antigenically selective vaccines for domestic animals
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4743562A (en) * 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
US4956452A (en) * 1987-06-14 1990-09-11 The University Of Maryland Monoclonal antibody which neutralizes multiple strains of infectious bursal disease virus
US4867975A (en) * 1988-01-27 1989-09-19 University Of Delaware Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors

Also Published As

Publication number Publication date
IL95867A0 (enExample) 1991-07-18
US6299874B1 (en) 2001-10-09
AU6755990A (en) 1991-04-28
DK0755684T3 (da) 2001-08-20
DK0495008T3 (da) 1997-10-13
US5397569A (en) 1995-03-14
CA2066661C (en) 2001-05-08
ES2158200T3 (es) 2001-09-01
US6136319A (en) 2000-10-24
CA2066661A1 (en) 1991-04-03
AU6714290A (en) 1991-04-28
EP0495008A1 (en) 1992-07-22
AU641958B2 (en) 1993-10-07
EP0495008B1 (en) 1997-04-02
EP0495008A4 (en) 1993-05-05
DE69030383D1 (de) 1997-05-07
DE69033728T2 (de) 2001-11-22
EP0755684B1 (en) 2001-04-25
DE69033728D1 (de) 2001-05-31
BR9007702A (pt) 1992-08-18
EP0755684A1 (en) 1997-01-29
ES2102368T3 (es) 1997-08-01
WO1991004749A1 (en) 1991-04-18
ATE200735T1 (de) 2001-05-15
US5871748A (en) 1999-02-16
IL95867A (en) 1994-10-07
DE69030383T2 (de) 1997-10-23

Similar Documents

Publication Publication Date Title
ATE150976T1 (de) Impfstoff-konjugate zur behandlung von vogelkrankheiten
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
NO912645D0 (no) Fremgangsmaate til aa forbedre fiskers og krepsdyrs motstand mot sykdommer.
ATE130762T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
ID21338A (id) Metoda untuk menghasilkan kekebalan aktif dengan vaksin gabungan
ATE20309T1 (de) Pharmazeutische zubereitung.
ATE429248T1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von virusinfektionen
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
DE3889581D1 (de) Monoklonale Antikörper gegen spezifische antigene Regionen des humanen Immundefizienzvirus und Methoden zur Verwendung.
DE69333730D1 (de) Impfstoff, der acemannan als adjuvans enthält
ATE39055T1 (de) Verfahren zur immunisierung von schweinen gegen die aujeszky-krankheit.
RU2044537C1 (ru) Способ стимуляции иммунитета кур
NO923749L (no) Bcrf1-antagonister for behandling av epstein-barr-virusinfeksjoner
RU96122226A (ru) Способ вакцинации против дифтерии детей с системными заболеваниями соединительной ткани
RU96123906A (ru) Способ и вакцина для профилактики и лечения иммунодефицитов, например рака
LV12736A (en) Method for producing concentrated antigen composition against swine erysipelas disease
Epstein The Vaccine Control of Virus-Induced Cancers
Whitfill et al. Method of treating infectious bursal disease virus infections
RU94024812A (ru) Способ профилактики полиомиелита на крайнем севере
ATE99956T1 (de) Newcastle-krankheitsvirus-impfstoff und methode fuer seine verwendung.
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
RU93005036A (ru) Способ лечения вируса иммунодефицита человека
CS578887A1 (en) Inactivated antigen of cattle's mucosal disease's virus
RU98105627A (ru) Вакцины